FY2026 EPS Estimates for REGENXBIO Raised by Leerink Partnrs
Investment analysts at Leerink Partnrs lifted their FY2026 EPS estimates for REGENXBIO in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now expects that the ...
Cantor Fitzgerald lifts PTC Therapeutics stock target to $113
Cantor Fitzgerald's analysts demonstrated a positive outlook on PTC Therapeutics (NASDAQ:PTCT), increasing the price target to $113.00 from the previous $76.00. The firm maintains an Overweight rating ...
the-tartan19h
New study on personalized medicine could speed up treatments for rare diseases
Personalized organoids — ‘mini-organs’ — may accelerate treatment for patients with rare genetic disorders. Courtesy of Europeana via Unsplash Across the globe, countless babies ...
The EMBO Journal16h
Type-2 innate signals are dispensable for skeletal muscle regeneration and pathology linked to Duchenne muscular dystrophy
Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...
PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges
PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...